Physician profile
Gemini J Bogie
NPI 1326029299
$848.47
in general payments reported to CMS, 2019-2025
12 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.04 · 2020: $17.91 · 2021: $38.63 · 2022: $258 · 2023: $142 · 2024: $206 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $291.59 | 2021-2025 | Argos |
| Abbvie INC. | $169.51 | 2022-2024 | Durysta |
| Dompe US, INC. | $80.90 | 2024-2025 | Oxervate |
| Glaukos Corporation | $52.95 | 2019-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $47.41 | 2024-2025 | Ic-8 Apthera Iol |
| Horizon Therapeutics Plc | $44.75 | 2023 | Tepezza |
| Amgen INC. | $44.41 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $35.67 | 2019-2020 | |
| Oyster Point Pharma, INC. | $31.36 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.80 | 2021 | |
| Ocular Therapeutix, INC. | $17.00 | 2024 | Dextenza |
| Harrow Eye, LLC | $15.12 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemini Bogie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.